register

News & Trends - Pharmaceuticals

Viatris joins forces with top surgeon to spearhead innovative screening model of care

Health Industry Hub | May 3, 2023 |

Pharma News: The healthcare system is facing a series of challenges that are impacting consumers in receiving timely access to care. However, the recent Strengthening Medicare Taskforce report has recommended several solutions to improve the delivery of quality care. One of the proposed solutions is to introduce new blended funding models that allow different health professionals to work together in delivering care.

In an interview with Health Industry Hub, Professor Toby Richards, Professor of Vascular Surgery, University of Western Australia and Cynthia Tan, Head of Medical Affairs, Viatris discussed a research partnership that highlights the potential to provide greater access to screening through pharmacies. This research aims to address a health issue that impacts a significant number of women.

Despite the benefits of the wider access to rapid antigen tests (RATs) through pharmacies during the pandemic, there has been some backlash from the Royal Australian College of General Practitioners (RACGP) on the UTI pharmacy pilot and the expanding role of pharmacists in delivering care. Professor Richards emphasised the key strategies and success factors within the research project that also aim to bring GPs on the care journey.

Mark Butler MP, Minister for Health and Aged Care, has also emphasised the need to end turf wars between different health professional groups to ensure that consumers receive equitable access to quality care.

The latest Productivity Commission Report has revealed that mounting out-of-pocket medical costs are causing more Australians to delay or avoid seeing their doctor or filling prescriptions. However, Professor Richards highlighted the affordability of the screening test and the population this new model of care aims to serve.

Innovative models can enhance equitable and timely access to quality care, by reducing the need for acute care and further pressure on the public hospital system that is deteriorating at a level not seen in the past 15 years.

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Roche's immunotherapy drug shows promising results for Australian patients with rare blood cancer

Roche’s immunotherapy drug shows promising results for Australian patients with rare blood cancer

Health Industry Hub | October 8, 2024 |

Pharma News: Roche’s immunotherapy drug has shown high response rates in patients with a rare form of blood cancer that […]

More


News & Trends - Pharmaceuticals

Government seals deal with industry for rare cancer therapy

Government seals deal with industry for rare cancer therapy

Health Industry Hub | October 8, 2024 |

Pharma News: Australian children and young adults diagnosed with high-risk neuroblastoma will continue to receive free access to a promising, […]

More


News & Trends - MedTech & Diagnostics

Abbott showcases leadless pacemaker system to local stakeholders

Abbott showcases leadless pacemaker system to local stakeholders

Health Industry Hub | October 8, 2024 |

MedTech & Diagnostics News: Leadless pacemakers are promising alternatives to transvenous pacing. Abbott hosted a stakeholder event at the recent […]

More


News & Trends - Pharmaceuticals

Australian scientists pivotal in new drug class from BMS

Australian scientists pivotal in new drug class from BMS

Health Industry Hub | October 8, 2024 |

Pharma News: The first new class of drug for schizophrenia in decades has been approved, offering a fresh approach by […]

More


This content is copyright protected. Please subscribe to gain access.